The Clinical Research Excellence (CRX08) conference starts in Brisbane tomorrow. We talk flu pandemics with plenary speaker Anne Kelso.

Scientists create comprehensive libraries of avian flu virus antibodies

Almost everywhere humans have gone in their peregrinations around the planet, the world's second most ubiquitous mammal, the black rat, Rattus rattus, has followed.

Method to better interrogate H5 flu virus protein developed by Australian and international researchers.

Scientists at CSIRO's Australian Animal Health Laboratory (AAHL) in Geelong have launched a potentially revolutionary research project aimed at reducing the threat of the lethal H5N1 avian influenza virus.

GlaxoSmithKline says early trials show its split antigen avian flu vaccine is effective against other strains.

An aberrant immune response - also observed in the bird flu virus H5N1 - may be the reason why the 1918 influenza pandemic killed so many healthy adults.

A comprehensive analysis of influenza A epitopes, the critical sites on the virus that are recognised by the immune system, has been published by researchers from California's La Jolla Institute for Allergy and Immunology (LIAI).

Melbourne's CSL (ASX:CSL) today reported a net profit after tax of AUD$176.4 million for the first half of the financial year, up 34 per cent from the previous first half, and has upgraded its full year profit forecast by about 15 per cent to $335 to $350 million.

The federal government is considering whether to protect vaccine company CSL (ASX:CSL) against lawsuits by patients who suffer adverse reactions from its bird flu vaccine if production is fast-tracked in the event of pandemic.

The Commonwealth government has outlined AUD$6.5 million in urgent funding for 33 research projects aiming to prevent, detect or control avian influenza and other respiratory disease outbreaks.